Abstract
Clopidogrel is an inhibitor of platelet aggregation, indicated for the prevention of ischemic stroke and in-stent thrombosis. However, it has a number of drawbacks, including an increased risk of hemorrhage; a clinical effect that is slow in onset and irreversible; a genetically determined variability in its clinical potency; and interactions with other commonly administered drugs.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Clopidogrel
-
Dose-Response Relationship, Drug
-
Hemorrhage / chemically induced*
-
Hemorrhage / prevention & control*
-
Humans
-
Platelet Aggregation Inhibitors / administration & dosage
-
Stroke / prevention & control*
-
Ticlopidine / administration & dosage
-
Ticlopidine / adverse effects
-
Ticlopidine / analogs & derivatives*
Substances
-
Platelet Aggregation Inhibitors
-
Clopidogrel
-
Ticlopidine